What are Renin blockers?

Renin blockers, more often known as renin inhibitors, form the category of drugs that suppress Renin. Renin is also known as angiotensinogenase and is the enzyme and main participant of the Renin-English system (RAS). In this hormonal system, which monitors the blood pressure of the body and the balance of water or liquid, Renin plays an important role in the extracellular volume of the body, which consists of substances outside the cell. It also plays a role in narrowing of arteries or arterial vasoconstriction.

RAS is named for the relationship between Renin and the peptide called angiotensin. It is created when Renin converts angiotensinogen, globular protein released mainly into the liver plasma, to angiotensin I. However, this version of the peptide is inactive. Angiotensin I is therefore angiotensin II, angiotensin II, angiotensin II, angiotensin II.

ie Renin I, angiotensin and angiotensin and angiotensin II. Angiotensin I, Renin I, Angiotensin I.s responsible for the process produced by angiotensin II that increases blood pressureand creates hypertension in two ways. Peptide takes care of the muscles that surround the blood vessels, especially arteries, thereby limiting and limiting the blood flow. Also, its release of hormonal aldosterone to increase sodium and water reabsorce and water from the kidneys contributes to hypertension and also increases the total extracellular volume and possibility of kidney failure.

The connection between Renin and hypertension was discovered at the end of the 19th century, when two physiologists noticed the development of high blood pressure in rabbits, that injection enzyme. At the end of the 20th century, two classes of drugs were developed: ACE and angiotensin II receptors or angiotensin receptor blockers (ARB), which focus on the different parts of the renin-angiotensin process. ACE inhibitors suppress an enzyme that changes angiotensin to angiotensin II, while Angiotensin II inhibits Arb.

Renin blockers are the latest group of medicines developed for the Ren processIn-English, specifically, when Renin turns angiotensinogen to angiotensin I. Pharmaceutical societies began to develop renin blockers when it was found that chronic use of hypertensive drugs in fact increased renin production. Renin blockers had to be invented to stop the process at the very beginning.

The first example of Renin blockers is Remikiren, which is based in Switzerland, the global medical company F. Hoffmann-la Roche Ltd. introduced in 1996. Another example is Aliskiren, which was approved by the Food and Drug Administration (FDA) in 2007. In other countries it is the trade name Tecturna.